

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * <u>Delaney David</u>  (Last) (First) (Middle) C/O CONCORD INVESTMENT PARTNERS LTD. 60 ST. CLAIR AVENUE EAST, SUITE 702  (Street) TORONTO A6 M4T 1N5  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Pasithea Therapeutics Corp. [ KTTA ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title below) X Other (specify below) Member of 10% owner group
	3. Date of Earliest Transaction (Month/Day/Year) 10/17/2022	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	10/17/2022		P		1,000 <sup>(1)</sup>	A	\$1.11	227,521	I	See footnote <sup>(2)</sup>

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person * <u>Delaney David</u>  (Last) (First) (Middle) C/O CONCORD INVESTMENT PARTNERS LTD. 60 ST. CLAIR AVENUE EAST, SUITE 702  (Street) TORONTO A6 M4T 1N5  (City) (State) (Zip)
---

1. Name and Address of Reporting Person * <u>Concord IP2 Ltd.</u>  (Last) (First) (Middle) C/O CONCORD INVESTMENT PARTNERS LTD. 60 ST. CLAIR AVENUE EAST, SUITE 702  (Street) TORONTO A6 M4T 1N5  (City) (State) (Zip)
--

1. Name and Address of Reporting Person \*

[Elderhill Corp](#)

(Last) (First) (Middle)

C/O CONCORD INVESTMENT PARTNERS LTD.  
60 ST. CLAIR AVENUE EAST, SUITE 702

(Street)

TORONTO A6 M4T IN5

(City) (State) (Zip)

**Explanation of Responses:**

1. The shares were purchased by Elderhill Corporation, of which David Delaney serves as sole director and President.
2. 191,321 shares are held by Concord IP2, Ltd., of which David Delaney serves as sole director and President, and 36,200 shares are held by Elderhill Corporation.

**Remarks:**

[/s/ David Delaney](#) [10/19/2022](#)

[/s/ David Delaney, President of  
Concord IP2 Ltd.](#) [10/19/2022](#)

[/s/ David Delaney, President of  
Elderhill Corporation](#) [10/19/2022](#)

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**